Remdesivir in Patients With Severe Kidney Dysfunction: A Secondary Analysis of the CATCO Randomized Trial

Abstract

This secondary analysis of a randomized clinical trial examines the risk of kidney or hepatic toxic effects among patients with impaired kidney function at baseline treated with remdesivir.

Conflict of interest statement

Conflict of Interest Disclosures: Dr Cheng reported receiving grants from the Canadian Institutes of Health Research and McGill Interdisciplinary Initiative in Infection and Immunity during the conduct of the study, fees (stock options) from GEn1E Lifesciences and Nomic Bio as a member of their scientific advisory boards, fees (equity) from Kanvas Biosciences as a cofounder of the company, consulting fees (honoraria) from Astra Zeneca, and research support from Cidara Therapeutics Scynexis Inc and Amplyx Pharmaceutics outside the submitted work. Dr Fowler reported receiving grants from the Canadian Institutes of Health Research during the conduct of the study. Dr Murthy reported receiving grants from Canadian Institutes of Health Research during the conduct of the study. Dr Sheehan reported receiving personal fees from Pfizer Canada, and personal fees from Merck Canada outside the submitted work. Dr Tseng reported personal consulting fees from Gilead Canada and personal fees from Pfizer Canada outside the submitted work. No other disclosures were reported.